Considerable studies have demonstrated the pivotal roles of matrix metalloproteinases (MMPs) in leukemia dissemination and extramedullary infiltration. Tissue inhibitors of matrix metalloproteinases (TIMPs) are multifunctional proteins with MMPs inhibitory effects. However, little is known about the application of TIMPs in the treatment of leukemia. Here, we investigated the effects of TIMP-3 overexpression via adenoviral gene delivery on the in vitro growth and invasiveness of leukemic cells and the in vivo progress of K562-derived xenografts in nude mice. The in vitro invasiveness of K562 cells was markedly impaired by AdTIMP-3 infection. Moreover, TIMP-3 significantly inhibited K562-derived angiogenic factors-induced proliferation, migration and bFGF-induced tube formation of endothelial cells (ECs) in vitro, and reduced VEGF-induced gelatinases expression and activation in ECs. Although TIMP-3 overexpression had no direct effect on the growth of K562 cells in vitro, repeated intratumoral injection of AdTIMP-3 significantly inhibited the growth of K562 xenografts in nude mice. Furthermore, lower microvessel density, less vessel maturity and increased apoptosis were observed in AdTIMP-3-treated K562 xenografts, suggesting the importance of antiangiogenic action of TIMP-3. These data demonstrated the potential of applying AdTIMP-3 as an effective antiangiogenic adjuvant in the treatment of leukemia progression.
Introduction
Degradation of the extracellular matrix (ECM) is a key event in tumor angiogenesis, invasion and metastasis. Proteolytic enzymes, including matrix metalloproteinases (MMPs) play major roles in this process. 1 MMPs, a family of zinc-dependent neutral endopeptidases, can degrade all components of ECM and basement membrane. MMPs are important in multiple physiological processes including embryo development, organ morphogenesis, angiogenesis and tissue remodeling. Augmented MMPs activities have been found in many types of tumors with increased angiogenesis and aggressiveness. Tissue inhibitors of metalloproteinases (TIMPs), which can be found in most tissues, are the major natural inhibitors of MMPs. 2 The four known TIMPs (TIMP-1, -2, -3, -4) form noncovalent complexes with all active MMPs as well as some pro-MMPs, thereby inhibiting the proteolytic activity of MMPs and the activation of pro-MMPs. The local balance of MMPs/TIMPs is critical for the maintenance of physiological ECM homeostasis. Disruption of this balance may result in serious diseases such as atherogenesis, rheumatoid arthritis and cancer progression. 3 The complicated balance of ECM turnover is also crucial for the structural and functional homeostasis of bone marrow (BM). The alteration in expression level or activity of MMPs will destroy the hematopoietic microenvironment, resulting in hematopoiesis aberration. 4 Leukemia can be characterized as a prototype of disseminated cancer with uncontrolled proliferation of immature hematopoietic cells in BM. Malignant transformation of the hematopoietic stem cells (HSCs) results in the blockade of terminal differentiation, rendering rapid accumulation of immature proliferative cells. 5 The abnormal blood cells aggregation may induce the collapse of cell-stroma interaction, leading to the subsequent egress of excessive immature cells from BM to peripheral blood and the infiltration into extramedullary organs. MMPs and TIMPs are proved to be essential for the invasion and angiogenesis of certain hematological malignancies. 6 TIMP-3, a unique multifunctional TIMP, binds tightly to ECM with heparan sulfate and chondroitin sulfate. The expression of TIMP-3 has been detected in normal tissues, such as epithelia, muscle, prostate and embryonic cytotrophoblast, but not in hematopoietic tissues. TIMP-3 can inhibit all MMPs tested so far and its overexpression can drastically retard tumor angiogenesis, invasion and metastasis in mice model. [7] [8] [9] [10] Recently, additional physiological functions have been attributed to TIMP-3, including inhibition of angiogenesis, 11 promotion of apoptosis 7, 8, 12, 13 and the modulation of tumor necrosis factor a (TNF-a) signal transduction. 14 TIMP-3 gene is also considered to be a tumor suppressor gene, as its expression is silenced in different types of cancer due to the promoter hypermethylation. 15 Adenovirusmediated overexpression of TIMP-3 induces apoptosis in several tumor cell lines, and exerts a cytotoxic bystander effect on uninfected tumor cells. 8 Therefore, TIMP-3 has been proved to be a promising candidate for gene therapy in several solid tumor models. Here, for the first time, we investigated the effects of TIMP-3 overexpression via adenoviral gene transfer on the growth and invasiveness of leukemic cells in vitro and the progress of K562-derived xenografts in nude mice in vivo.
Materials and methods

Generation of recombinant adenovirus carrying TIMP-3
The replication-deficient recombinant adenovirus AdTIMP-3 and control virus AdGFP were constructed using AdEasyt system with some modifications. Briefly, human TIMP-3 cDNA was obtained by RT-PCR from human placenta tissue with primers: 5 0 -T ATA AGA TCT GCT GCG GCA ATG ACC-3 The invasive capacity of infected/uninfected K562 cells was analyzed in a modified ECM-based assay as described. 16, 17 Briefly, 6.5-mm diameter polycarbonate filters (8 mm-pore size) (Transwell; Corning-Costar, Cambridge, MA, USA) were coated with 50 ml of ECM gel (Sigma). The lower chambers were filled with serum-free RPMI-1640, supplemented with 100 ng/ml VEGF as chemoattractant. The cells were preinfected 24 h before assay and resuspended in serum-free RPMI-1640 containing 0.5% BSA. 1 Â 10 5 cells were added to the upper chambers in triplicate and incubated at 371C for 24 h. Migrated cells were collected from the lower compartment and counted with FACS. The rate of invasion was expressed in percentages of migrated cells as a fraction of the total number of cells placed in the upper compartment.
K562 cells growth and invasion assays
Endothelial cell proliferation and migration assays 2 Â 10 4 HUVECs were seeded into 24-well plates. After 24 h, the medium was replaced with M199 containing 20% FCS and twofold concentrated CM from infected/uninfected K562 cells (v/v ¼ 1:1). After 48 h, cells were trypsinized and counted. Migration assay was performed in Transwell chamber (8 mmpore size) (Corning-Costar, Cambridge, MA, USA) in triplicate. A volume of 500 ml CM from infected/uninfected K562 cells was placed in the lower chambers. 10 5 HUVECs, resuspended in serum-free RPMI-1640 containing 0.5% BSA, were placed in the upper chambers. After 4 h of incubation at 371C, cells in the lower chambers were collected, and counted by FACS at least three times.
In vitro EC tube formation assay
Endothelial tube formation assays were performed in 96-well plates. In all, 60 ml ECM gel (Sigma) was plated in each well and polymerized for 30 min at 371C. 2 Â 10 4 HUVECs were resuspended in 50 ml of CM from infected/uninfected K562 cells supplemented with 10 ng/ml bFGF. Cells were seeded on the gel and incubated for 6 h at 371C. Endothelial tube formation was examined using a phase-contrast microscope and photographed.
Gelatinases zymographic analysis in ECs
To explore the effect of TIMP-3 on the expression and activation of gelatinases (MMP-2, MMP-9) in ECs, gelatin zymography was performed as described. 17 The 48 h CM from infected/uninfected HUVECs cultured in serum-free M199 containing 10 ng/ml VEGF were analyzed by substrate-gel zymography, using a 10% SDS-PAGE copolymerized with 2 mg/ml gelatin (Sigma) in nonreducing conditions. Following electrophoresis, the gels were washed three times in a 2.5% (V/V) Triton-X-100 solution for 30 min and incubated overnight in developing buffer (50 mM Tris, pH 8.0, 50 mM NaCl, 10 mM CaCl 2 and 0.05% Brij35) at 371C. The gels were stained in 0.5% Coomassie R-250 for 1 h followed by destaining with 40% (v/v) methanol/10% (v/v) acetic acid solution. The proteolytic activities of the gelatinases were detected as unstained bands on a blue-stained background.
Murine tumor models
Female Balb/c athymic nude mice (5 weeks old, Center for experimental animals, Chinese Academy of Medical Sciences) were housed in specific pathogen-free conditions. K562 cells (1 Â 10 7 in 100 ml of serum-free RPMI-1640 medium) were injected subcutaneously (s.c.) into the right dorsal of mice. When tumors reached the mean size of 100 mm 3 , an intratumoral injection of 2 Â 10 9 PFU AdTIMP-3 virus or AdGFP control virus or the same volume PBS was carried out at days 0, 5 and 10. Tumors were measured with a caliper every 3 days for 21 days, and tumor volumes were calculated by the formula (L Â W 2 /2), where L represents the largest tumor diameter and W represents the smallest tumor diameter. Tumors were harvested and frozen in liquid nitrogen or fixed in formaldehyde. The experiments were approved by the National Cancer Institute's Animal Care and Use Committee, and all animal care was in accordance with institutional guidelines.
Western blot analysis of TIMP-3 expression
Protein lysates from excised tumors and 10-fold concentrated CM from infected/uninfected K562 cells were separated on a 
Histological analysis
Formalin-fixed (10%), paraffin-embedded tumor specimens were analyzed for tumor microvessel density (MVD) and apoptosis. Tumor microvessels were probed by a rat anti-mouse CD31 antibody (1:200; PharMingen, San Diego, CA, USA) and were visualized with DAB using a Streptavidin-Horseradish Peroxidase kit (Golden Bridge, Beijing, China). Stained tumor sections were scanned under low power and the areas of greatest CD31-positive density were chosen for analysis according to the procedure of Weidner et al. 18 The number of individual brown staining endothelial cells or clusters was counted at Â 200 magnification. A total of five randomly chosen microscopy fields were evaluated for each tissue specimen. The MVD was expressed as the number of CD31-positive vessels per microscopy field. Immunolocalization of a-smooth muscle actin (a-SMA) in vascular smooth muscle cells was verified by staining these cells with a biotinylated mouse anti-human a-SMA monoclonal antibody (clone 1A4, DAKO, Glostrup, Denmark).
Apoptosis analysis was performed on formalin-fixed, paraffinembedded tumor sections with an in situ Cell Death Detection kit (TUNEL) according to the manufacturer's instructions (Roche Molecular Biochemicals, Germany).
Statistical analysis
All data are presented as mean7s.d. Student's t-test was used to analyze the statistical differences in the samples using the statistical software SPSS package (SPSS, Chicago, IL, USA). P-values less than 0.05 were considered significant.
Results
Construction of recombinant adenovirus
Recombinant adenovirus encoding GFP with/without TIMP-3 (AdTIMP-3, AdGFP) were propagated and concentrated to a titer of 1.25 Â 10 11 PFU/ml and 8 Â 10 10 PFU/ml, respectively. The green fluorescence of infected cells was used to confirm the expression of GFP and track the expression of TIMP-3 in vitro. The secretion of TIMP-3 from infected K562 cells and tumor tissues was determined with Western blot. The unglycosylated (21 kDa) and glycosylated (30 kDa) forms of TIMP-3 could be detected in the AdTIMP-3-infected K562-conditioned medium and tumor lysates from AdTIMP-3-treated mice (Figure 3a) .
In vitro characterization of AdTIMP-3-infected K562 cells K562 cells were infected with AdTIMP-3 or AdGFP at various MOI, and the infection efficiency was determined by GFP expression using FACS. Above 80% of the infected cells showed strong green fluorescence at 200 MOI. The cell cycle and cell viability did not change after infection. As shown in Figure 1a , there was no significant growth difference among uninfected, AdTIMP-3-and AdGFP-infected K562 cells. However, the overexpression of TIMP-3 significantly inhibited the invasiveness of AdTIMP-3-infected K562 cells as compared with uninfected and AdGFP-infected K562 cells (Figure 1b) .
Inhibition of ECs proliferation, migration and tube formation by AdTIMP-3-infected K562 CM
To evaluate the effects of high level TIMP-3 on the growth, migration and tube formation of endothelial cells, CM from infected/uninfected K562 cells were assayed on HUVECs. The growth of AdTIMP-3-infected (20 MOI) HUVECs in normal medium did not show significant change as compared with uninfected or AdGFP-infected (20 MOI) HUVECs (data not shown), whereas the proliferation of HUVECs cultured in the CM from AdTIMP-3-infected K562 cells decreased 1.8-fold at 48 h as compared with that cultured in the CM from AdGFP-infected or uninfected K562 cells (Figure 2A ). These results indicated that this ECs growth inhibition was not due to the direct effect of TIMP-3 on HUVECs.
EC migration assays were performed in Transwell chambers using CM from infected/uninfected K562 cells as chemoattractant. As shown in Figure 2B , the CM from AdTIMP-3-infected K562 caused a two-fold decrease of HUVEC migration as compared with the CM from AdGFP-infected or uninfected K562 cells (Po0.001).
When plated on ECM gel, endothelial cells were capable of forming capillary-like structures in response to bFGF. The effects of TIMP-3-containg K562 CM on the tube formation ability of HUVECs were tested on ECM gel layer. HUVECs formed capillary-like tube network in the presence of uninfected or 
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AdGFP-infected K562 CM plus bFGF. There was a significant decrease in the number and length of EC tubes in TIMP-3-containing CM plus bFGF ( Figure 2C ). In conclusion, TIMP-3 could inhibit the K562-secreted angiogenic factors induced proliferation and migration of ECs, and bFGF-activated tube formation.
Inhibition of gelatinases expression and activation of ECs by TIMP-3
Gelatin zymography was performed to examine the effect of TIMP-3 on the expression and activation of gelatinases in VEGFstimulated ECs. The results showed that overexpression of TIMP-3 in HUVECs inhibited the expression of MMP-9 and pro-MMP-2, and the activation of pro-MMP-2 as well ( Figure 2D ).
Inhibition of xenograft tumor growth by AdTIMP-3 in vivo
To evaluate the in vivo effects of TIMP-3 overexpression, AdTIMP-3 virus was intratumorally injected at days 0, 5 and 10. TIMP-3 overexpression markedly inhibited tumor growth as compared with control groups. AdTIMP-3-treated tumors showed a pale and less vascularity appearance (Figure 4Aa-c) . The average volume of xenograft tumors in AdTIMP-3-treated (Figure 4Ca-c) . The coverage of a-SMA-positive periendothelial mesenchymal cells or pericytes cells around vascular endothelial cells is an important marker for blood vessel maturity. 19 The average number of a-SMA-positive cells per 200 Â field in AdTIMP-3-treated group was markedly lower (3.271.2) than those in AdGFP-treated (10.272.4) and PBS-treated groups (10.671.9) (Figure 4Da-c) . These results demonstrated that AdTIMP-3 treatment notably suppressed the angiogenesis and vascular maturation in K562-derived tumors.
In AdTIMP-3-treated tumors, large necrotic areas containing numerous apoptotic cells were prominent. In tumors treated with PBS or AdGFP, only small necrosis and a spot of apoptotic cells were observed (Figure 4Ba-c, Ea-c) . Although studies have shown TIMP-3 as an apoptosis inductor and growth inhibitor in several tumor cell lines, our in vitro studies demonstrated that the growth kinetics of K562 cells did not change by the infection of AdTIMP-3 as compared with the controls. These results suggested that the antileukemic xenografts effect of TIMP-3 is attributable to the significant inhibition of angiogenesis but not to the direct effect of TIMP-3 overexpression in tumor cells.
Discussion
Accumulating evidence shows that MMPs play crucial roles in the progression of certain hematological malignancies, including leukemia dissemination and extramedullary infiltration. MMPs may also promote pathological BM angiogenesis and leukemic cells survival/growth via ECM/cell membrane-bound growth factors release. 20, 21 The present study was therefore designed to explore whether TIMP-3 could interfere the roles of MMPs in the pathogenesis of leukemia, a particular disseminated cancer. Human myelogenous leukemia cell line K562 was chosen for its high invasiveness and the capability to form xenograft tumors in mice. We found efficient secretion of TIMP-3 in K562 cells and K562-derived tumors after recombinant adenovirus AdTIMP-3 infection. Although TIMP-3 has been shown to promote apoptosis in some types of tumor cell lines via stabilization of death receptors and activation of the Fas pathway, 22 as for K562 cells line, TIMP-3 overexpression had no direct effect on its growth kinetics. Nevertheless, the invasiveness across ECM gel of K562 cells was markedly impaired by AdTIMP-3 infection. K562 constitutively secretes MMP-2, MMP-7 and MMP-9, which are response for its invasion capacity. 17 The result suggested that the dramatic inhibition in K562 invasiveness was due to the MMPs enzymatic inhibition activity of TIMP-3.
TIMP-3 can directly block the binding of VEGF to VEGF receptor-2 and inhibit downstream angiogenic signal transduction. 23 K562 spontaneously secretes angiogenic factors including VEGF and bFGF, which not only conduce to the invasive ability but also form autocrine loops to support the survival/ proliferation of leukemic cells. 16, 24 To minimize the interference of other factors in serum, we used serum-free CM from infected/ uninfected K562 cells to investigate their effects on human endothelial cells. Although direct AdTIMP-3 infection had no effects on the growth of HUVECs, TIMP-3 significantly inhibited K562-derived angiogenic factors-induced proliferation, migration and bFGF-induced tube formation of HUVECs in vitro, and reduced VEGF-induced MMPs expression and activation in ECs.
Subsequent in vivo experiments showed that intratumoral administration of AdTIMP-3 severely inhibited the growth of K562 xenografts in nude mice. The MVD was much lower in AdTIMP-3-treated tumors accompanied with lower vessel maturity as compared with the control groups. Although TIMP-3 overexpression had no proapoptosis effect on K562, increased apoptosis and necrosis were found in AdTIMP-3-treated K562 xenografts, which may be a consequence of the antiangiogenic action of TIMP-3. As shown in solid tumor models, the antiangiogenic action of TIMP-3 may partly be due to its MMPs inhibitory effects. It has also been proved that TIMP-3 can inhibit vascular smooth muscle cell invasion and induce smooth muscle cell apoptosis through the death domain within its Nterminal. 12, 13 This may be the reason of lower vessel maturity in AdTIMP-3-treated tumors. In brief, these results demonstrate that antiangiogenic treatment with adenovirus-mediated TIMP-3 can retard the progression of K562-derived xenografts by suppression of angiogenesis in the tumors without affecting the proliferation of leukemic cells.
Numerous studies have demonstrated that synthetic MMP inhibitors (MMPIs) can inhibit the growth of a variety of tumors in murine xenograft models. Currently, these synthetic MMPIs are under clinical trials. SI-27 and METVAN are two synthetic MMP inhibitors, which can suppress growth and induce apoptosis in human leukemic cell lines as well as in primary leukemic cells from acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML) and chronic myelogenous 27, 28 Nillson et al. 29 have designed a new adenoviral vector Ad5F35-GFP on the basis of Ad5 vector by modification of viral fiber gene. The Ad5F35-GFP vector can transduce quiescent primitive hematopoietic progenitor cells and leukemia stem cells efficiently, which may facilitate the development of novel gene therapy treatment in leukemia. In the present study, in order to avoid unexcepted systematic adverse reaction, we built a subcutaneous tumor model to simulate the leukemic tumor growth and adopted intratumoral administration to treat the xenografts. Further investigation might be designed to apply tropism-retargeted adenoviral vector to mediate the high expression of TIMP-3 in leukemic cells on a disseminated model.
Altogether, our data demonstrated the potential of utilizing adenovirus for TIMP-3 gene transfer as an antileukemic strategy in vivo. For the first time, we showed that TIMP-3 overexpression can impair the invasiveness of leukemic cells in vitro and retard tumor growth in vivo by inhibiting leukemic proangiogenic factors-induced angiogenesis. Targeting angiogenesis represents a new strategy for the development of antileukemic therapies. It has been suggested that the proliferating endothelial cells stimulated by leukemic-derived angiogenic factors may release growth factors that can support leukemic cell growth by a paracrine loop mechanism. 21 Therefore, inhibiting the angiogenesis can reduce growth factors production, thereby retarding leukemic progression. Although the treatment of AdTIMP-3 alone could not completely suppress the growth of leukemic xenografts, which may be due to the multiple nosogenesis in leukemia progression, TIMP-3 gene therapy with the application of adenoviral vector possessing hematopoietic cell tropism in combination with conventional antileukemia treatment may represent a promising strategy in the treatment of leukemia progression.
